51 results match your criteria: "Extremadura University Hospital and Medical School[Affiliation]"

Article Synopsis
  • This international guideline suggests enhancing clozapine package inserts by implementing ancestry-based dosing and titration to reduce adverse drug reactions (ADRs).
  • Clozapine, a powerful medication, has a narrow therapeutic range and is highly associated with toxicity, especially in certain populations; it is especially risky due to its high rates of pneumonia-related mortality.
  • The guideline outlines six personalized dosing schedules based on ancestry and metabolic activity, recommending varying daily doses of clozapine tailored to individual patient profiles to minimize the risk of ADRs.
View Article and Find Full Text PDF

Testicular cancer is an aggressive malignancy with a rising incidence rate across the globe. Testicular germ cell tumors are the most commonly diagnosed cancers, and surgical removal of the testes is often a radical necessity along with chemotherapy and radiotherapy. While seminomas are receptive to radiotherapy as well as chemotherapy, non-seminomatous germ cell tumors respond to chemotherapy only.

View Article and Find Full Text PDF

Transient enhanced cell division by blocking DNA synthesis in .

Microbiology (Reading)

June 2020

Departamento de Bioquímica Biología Molecular y Genética, Universidad de Extremadura, Badajoz 06071, Spain.

Duplication of the bacterial nucleoid is necessary for cell division hence specific arrest of DNA replication inhibits divisions culminating in filamentation, nucleoid dispersion and appearance of a-nucleated cells. It is demonstrated here that during the first 10 min however, enhanced residual divisions: the proportion of constricted cells doubled (to 40%), nucleoids contracted and cells remodelled dimensions: length decreased and width increased. The preliminary data provides further support to the existence of temporal and spatial couplings between the nucleoid/replisome and the sacculus/divisome, and is consistent with the idea that bacillary bacteria modulate width during the division process exclusively.

View Article and Find Full Text PDF

4th ESPT summer school: precision medicine and personalised health.

Pharmacogenomics

May 2019

CANSEARCH Research Laboratory, Department of Paediatrics, Faculty of Medicine, Geneva University, 1205 Geneva, Switzerland.

In September 2018, the European Society of Pharmacogenomics and Personalised Therapy (ESPT), with the support of the Swiss Personalized Health Network (SPHN), organized its 4th biennial summer school, entitled 'Precision Medicine and Personalised Health' (Campus Biotech, Geneva, Switzerland; www.esptsummerschool.eu/ ).

View Article and Find Full Text PDF

Carbamazepine adverse drug reactions.

Expert Rev Clin Pharmacol

July 2018

e Department of Biological Systems , Metropolitan Autonomous University, Coyoacán, Mexico City , Mexico.

Carbamazepine (CBZ) is used for the treatment of epilepsy and other neurological and psychiatric disorders. The occurrence of adverse reactions (ADRs) to CBZ can negatively impact the quality of life of patients, as well as increase health-care costs. Thus, knowledge of CBZ-induced ADRs is important to achieve safer treatment outcomes.

View Article and Find Full Text PDF

Background: Hyperprolactinemia is a common side-effect of antipsychotics (APs), which may trigger serious secondary problems and compromise the adherence to treatment which is crucial for prognosis, especially in patients presenting with a first-episode of psychosis (FEP).

Aims: We evaluated, in some cases for the first time, the effect of polymorphisms in multiple candidate genes on serum prolactin (PRL) levels in an AP-treated FEP cohort recruited in the multicenter PEPs study (Phenotype - genotype and environmental interaction; Application of a predictive model in first psychotic episodes).

Methods: PRL concentration was measured in serum from 222 patients.

View Article and Find Full Text PDF

We present allele frequencies involving 39 pharmacogenetic biomarkers studied in Brazil, and their distribution on self-reported race/color categories that: (1) involve a mix of perceptions about ancestry, morphological traits, and cultural/identity issues, being social constructs pervasively used in Brazilian society and medical studies; (2) are associated with disparities in access to health services, as well as in their representation in genetic studies, and (3), as we report here, explain a larger portion of the variance of pharmaco-allele frequencies than geography. We integrated a systematic review of studies on healthy volunteers (years 1968-2017) and the analysis of allele frequencies on three population-based cohorts from northeast, southeast, and south, the most populated regions of Brazil. Cross-validation of results from these both approaches suggest that, despite methodological heterogeneity of the 120 studies conducted on 51,747 healthy volunteers, allele frequencies estimates from systematic review are reliable.

View Article and Find Full Text PDF

Multiple adverse drug reactions and genetic polymorphism testing: A case report with negative result.

Medicine (Baltimore)

November 2017

Department of Clinical Pharmacology, Hospital Universitari Germans Trias i Pujol, Barcelona Department of Pharmacology, Therapeutics, and Toxicology, Universitat Autònoma de Barcelona, Barcelona Department of Psychiatry, Hospital Universitari Germans Trias i Pujol, Barcelona FIDMAG Research Foundation, Barcelona Department of Anesthesiology and Reanimation, Pain Unit, Hospital Universitari Germans Trias i Pujol, Barcelona CICAB Clinical Research Center, Extremadura University Hospital and Medical School, Badajoz, Spain.

Rationale: Defects in drug metabolic pathways could explain why some patients have a history of multiple adverse drug reactions (ADR); therefore we aimed to analyze genetic polymorphisms in a patient with multiple ADR related to drugs with a common hepatic metabolic pathway through CYP2D6.

Patient Concerns: We report a patient with psychosis and hypertension related to amitriptyline, tramadol, and duloxetine within a 2-year period.

Interventions And Outcomes: A pharmacogenetic test was performed to assess the causative role of the CYP2D6 enzyme, but did not demonstrate a metabolic deficiency.

View Article and Find Full Text PDF

Therapeutic Drug Monitoring of Fluoxetine, Norfluoxetine and Paroxetine: A New Tool Based on Microextraction by Packed Sorbent Coupled to Liquid Chromatography.

J Anal Toxicol

September 2017

Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.

The present article reports the first liquid chromatography (LC) assay for the simultaneous quantification of fluoxetine (FLU), its metabolite norfluoxetine (NFLU) and paroxetine (PAR) in human plasma, applying the microextraction by packed sorbent (MEPS) technology in sample preparation. Chromatographic analysis of FLU, NFLU and PAR was achieved in <13 min on a reverse-phase C18 column using isocratic elution and fluorescence detection (FLD). The mobile phase was composed by an aqueous solution of 25 mM sodium phosphate monobasic anhydrous and 7.

View Article and Find Full Text PDF

Global precision medicine demands characterization of drug metabolism and phenotype variation in diverse populations, including the indigenous societies. A related question is the extent to which CYP450 drug metabolizing enzyme genotype and phenotype data are concordant and whether they can be used interchangeably. These issues are increasingly debated as precision medicine continues to expand as a popular research topic worldwide.

View Article and Find Full Text PDF

Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients.

Eur Neuropsychopharmacol

July 2017

Dept. Pathological Anatomy, Pharmacology and Microbiology, University of Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Psychiatry Department, Hospital General Universitario Gregorio Marañón, Spain; Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, CIBERSAM, Madrid, Spain; Department of Psychiatry, Hospital de Sant Pau, Barcelona, Spain; BIOARABA Health Research Institute, OSI Araba. University Hospital, University of the Basque Country, CIBERSAM, Vitoria, Spain; Instituto de Investigación Sanitaria Aragón (IIS Aragón), Dept. of Medicine and Psychiatry, University Zaragoza, CIBERSAM, Spain; Clinic Hospital Valencia, INCLIVA, Valencia University, CIBERSAM, Spain; Hospital del Mar Medical Research Institute (IMIM), Barcelona, Universitat Autonoma de Barcelona, Barcelona. CIBERSAM, Spain; Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain; Department of Child and Adolescent Psychiatry and Psychology, SGR489, Institute of Neuroscience, Hospital Clínic of Barcelona, IDIBAPS, CIBERSAM, Spain; Psychiatry Department, Bellvitge University Hospital-IDIBELL, Barcelona, Spain; Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain; Psychiatry Department, University of Oviedo, Oviedo, Spain; Araba University Hospital, Bioaraba Research Institute, Vitoria, Spain; University of the Basque Country (UPV/EHU), Department of Neurosciences. CIBERSAM, Spain; Cruces University Hospital, Department of Psychiatry, BioCruces Health Research Institute, Vizcaya, Spain; Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain; CIBERSAM, Barcelona, Spain; Research Unit, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain; FIDMAG Hermanas Hospitalarias Research Foundation, Barcelona, Spain; Neuroscience Research Australia, Sydney, NSW, Australia; School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia; ARC Centre of Excellence in Cognition and its Disorders, Sydney, NSW, Australia; Hospital Ramon y Cajal, Universidad de Alcala, IRYCIS, CIBERSAM, Madrid, Spain; Department of Psychiatry, Complejo Hospitalario de Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Spain; Mental Health Centre of Catarroja, University of Valencia, CIBERSAM, Spain.

Risperidone (R) is the most prescribed antipsychotic drug for patients with a first episode of psychosis (FEP). In a naturalistic cohort of chronic psychiatric inpatients, we demonstrated that clinicians adjust R dosage by CYP2D6 activity, despite being blinded to the genotype, which we described as an "intuitive pharmacogenetic" process. The aim of the present study is to replicate our previous findings of intuitive pharmacogenetic in a cohort of FEP patients using CYP2D6 phenotype extrapolated from genotypes.

View Article and Find Full Text PDF

A long-standing question and dilemma in precision medicine is whether and to what extent genotyping or phenotyping drug metabolizing enzymes such as CYP2D6 can be used in real-life global clinical and societal settings. Although in an ideal world using both genotype and phenotype biomarkers are desirable, this is not always feasible for economic and practical reasons. Moreover, an additional barrier for clinical implementation of precision medicine is the lack of correlation between genotype and phenotype, considering that most of the current methods include only genotyping.

View Article and Find Full Text PDF

Public policies to stop or reduce cigarette smoking and exposure to secondhand smoke and associated diseases have yielded successful results over the past decade. Yet, the growing worldwide popularity of another form of tobacco consumption, water pipe smoking, has received relatively less attention. To the best of our knowledge, no study to date has evaluated the effects of water pipe smoking on cytochrome P450 (CYP450) activities and drug interaction potential in humans, whereas only limited information is available on the impact of secondhand smoke on drug metabolism.

View Article and Find Full Text PDF

Lasmiditan for the treatment of migraine.

Expert Opin Investig Drugs

February 2017

f Department of Clinical and Molecular Medicine , Sapienza University, Rome , Italy.

Migraine is one of the most common diseases in the world, with high economical and subjective burden. Migraine acute therapy is nowadays based on specific and non-specific drugs but up to 40% of episodic migraineurs still have unmet treatment needs and over 35% do not benefit from triptans administration. Serotonin-1F receptors have been identified in trigeminal system and became an ideal target for anti-migraine drug development as potential trigeminal neural inhibitors.

View Article and Find Full Text PDF

Can the CEIBA Cocktail Designed for Human Cytochrome P450 Enzymes be Used in the Rat for Drug Interaction Studies?

J Pharm Pharm Sci

November 2017

Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Pólo das Ciências da Saúde, Azinhaga de Santa Comba, Coimbra, Portugal. Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal. Health Sciences Research Centre, University of Beira Interior, Rua Marquês d'Ávila e Bolama, Covilhã, Portugal. Clinical Research Centre, Extremadura University Hospital and Medical School, Badajoz, Spain.

Purpose - The CEIBA cocktail consisting of caffeine (CAF), omeprazole (OZ), dextromethorphan (DM) and losartan (LOS) was previously proposed for the clinical phenotyping of five major human cytochrome P450 (CYP) isoenzymes. This work aimed to assess the usefulness of CEIBA cocktail to study non-clinical drug interactions in the rat. Methods - Wistar rats were divided into five groups to receive a single-oral dose of each probe drug (CAF, OZ, LOS, DM), individually or in combination as a cocktail.

View Article and Find Full Text PDF

Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment.

Mol Psychiatry

August 2017

Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

The polymorphic CYP2C19 enzyme metabolizes psychoactive compounds and is expressed in the adult liver and fetal brain. Previously, we demonstrated that the absence of CYP2C19 is associated with lower levels of depressive symptoms in 1472 Swedes. Conversely, transgenic mice carrying the human CYP2C19 gene (2C19TG) have shown an anxious phenotype and decrease in hippocampal volume and adult neurogenesis.

View Article and Find Full Text PDF

Genetic variations within the cytochrome P450 (CYP450) superfamily of drug metabolizing enzymes confer substantial person-to-person and between-population differences in pharmacokinetics, and by extension, highly variable clinical effects of medicines. In this context, "personalized medicine," "precision medicine," and "stratified medicine" are related concepts attributed to what is essentially targeted therapeutics and companion diagnostics, aimed at improving safety and effectiveness of health interventions. We report here, to the best of our knowledge, the first comparative clinical pharmacogenomics study, in an Ecuadorian population sample, of five key CYP450s involved in drug metabolism: CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.

View Article and Find Full Text PDF

Intra- and/or inter-individual variability in drug response is mainly a result of either subtherapeutic or supratherapeutic plasma levels of the active drugs and their metabolites, with this variability mainly being influenced by differences in the rate of drug metabolism. Indeed, drug metabolism is largely determined by genetic polymorphism in the CYP enzymes, which are responsible for approximately 85% of the drug metabolism process. However, this genetic heterogeneity can accurately predict actual drug metabolizing capacity (oxidation phenotype) for some individuals: poor metabolizers (PMs), who cannot produce the drug metabolizing enzymes, and 20% of ultra-rapid metabolizers.

View Article and Find Full Text PDF

Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response.

Ther Adv Neurol Disord

September 2016

Department of Molecular Medicine, Sant'Andrea Medical Center, Sapienza University of Rome, Italy Regional Referral Headache Center, Sant'Andrea Hospital, Rome, Italy.

Migraine is a multifactorial, neurological and disabling disorder, also characterized by several autonomic symptoms. Triptans, selective serotonin 5-HT1B/1D agonists, are the first-line treatment option for moderate-to-severe headache attacks. In this paper, we review the recent data on eletriptan clinical efficacy, safety, and tolerability, and potential clinically relevant interactions with other drugs.

View Article and Find Full Text PDF

Acute, transitional and long-term cluster headache treatment: pharmacokinetic issues.

Expert Opin Drug Metab Toxicol

September 2016

c Department of Molecular Medicine, Sant'Andrea Medical Center , Sapienza University of Rome, Rome , Italy.

Introduction: The cornerstones of cluster headache therapy are based on the tripod of acute, transitional and preventative treatments that respectively aim to the control of the bouts, the transitional suppression of the relapse and the prevention of the entire cluster period. Particularly in chronic cluster headache, where a long-term preventative therapy is necessary, multiple drug regimens increase the risk of drug-drug interactions leading to variability in the clinical efficacy and to potentially harmful adverse effects.

Areas Covered: We focused on how clinically significant pharmacokinetic drug-drug and food-drug interactions can be carefully managed both in cluster headache patients with a progressive frequency of bouts and in chronic cluster headache sufferers.

View Article and Find Full Text PDF

This study investigated whether the risk of presenting antipsychotic (AP)-induced extrapyramidal symptoms (EPS) could be related to single-nucleotide polymorphisms (SNPs) in a naturalistic cohort of first episode psychosis (FEP) patients. Two hundred and two SNPs in 31 candidate genes (involved in dopamine, serotonin and glutamate pathways) were analyzed in the present study. One hundred and thirteen FEP patients (43 presenting EPS and 70 non-presenting EPS) treated with high-potency AP (amisulpride, paliperidone, risperidone and ziprasidone) were included in the analysis.

View Article and Find Full Text PDF